Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity treatments continue to improve. The Food and Drug Administration said Friday that drugmaker Novo Nordisk can meet present and future demand in the U.S. But patients may still see some limited supply disruptions as the drugs move from the manufacturer to distributors and then pharmacies. The injectable drugs have been in shortage since 2022. In December, the FDA declared that the shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., also had been resolved.
